Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
Journal of Clinical Oncology · 10.04.2023 · 41 (11) · 2007-2019
DOI: 10.1200/jco.22.01134 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.04.2023. Verfasst von Margaret A Tempero und 31 weiteren Autor:innen. Beteiligte Einrichtung: University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Die Arbeit wurde bisher 147-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE This randomized, open-label trial compared the efficacy and safety of adjuvant nab-paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic ductal adenocarcinoma (ClinicalTrials.gov identifier: NCT01964430 ). METHODS We assigned 866 treatment-naive patients with pancreatic ductal adenocarcinoma to nab-paclitaxel (125 mg/m 2 ) + gemcitabine (1,000 mg/m 2 ) or gemcitabine alone to one 30-40 infusion on days 1, 8, and 15 of six 28-day cycles. The primary end point was independently assessed disease-free survival (DFS). Additional end points included investigator-assessed DFS, overall survival (OS), and safety. RESULTS Two hundred eighty-seven of 432 patients and 310 of 434 patients completed nab-paclitaxel + gemcitabine and gemcitabine treatment, respectively. At primary data cutoff (December 31, 2018; median follow-up, 38.5 [interquartile range [IQR], 33.8-43 months), the median independently assessed DFS was 19.4 ( nab-paclitaxel + gemcitabine) versus 18.8 months (gemcitabine; hazard ratio [HR], 0.88; 95% CI, 0.729 to 1.063; P = .18). The median investigator-assessed DFS was 16.6 (IQR, 8.4-47.0) and 13.7 (IQR, 8.3-44.1) months, respectively (HR, 0.82; 95% CI, 0.694 to 0.965; P = .02). The median OS (427 events; 68% mature) was 40.5 (IQR, 20.7 to not reached) and 36.2 (IQR, 17.7-53.3) months, respectively (HR, 0.82; 95% CI, 0.680 to 0.996; P = .045). At a 16-month follow-up (cutoff, April 3, 2020; median follow-up, 51.4 months [IQR, 47.0-57.0]), the median OS (511 events; 81% mature) was 41.8 ( nab-paclitaxel + gemcitabine) versus 37.7 months (gemcitabine; HR, 0.82; 95% CI, 0.687 to 0.973; P = .0232). At the 5-year follow-up (cutoff, April 9, 2021; median follow-up, 63.2 months [IQR, 60.1-68.7]), the median OS (555 events; 88% mature) was 41.8 versus 37.7 months, respectively (HR, 0.80; 95% CI, 0.678 to 0.947; P = .0091). Eighty-six percent ( nab-paclitaxel + gemcitabine) and 68% (gemcitabine) of patients experienced grade ≥ 3 treatment-emergent adverse events. Two patients per study arm died of treatment-emergent adverse events. CONCLUSION The primary end point (independently assessed DFS) was not met despite favorable OS seen with nab-paclitaxel + gemcitabine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
- Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
- Memorial Sloan Kettering Cancer Center, New York, NY.
- Thomas Jefferson University Hospital, Philadelphia, PA.
- Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
- Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea.
ORCID-Profile: Margaret A Tempero, Eileen M O'Reilly, Jordan Winter, Do-Youn Oh, Chung-Pin Li, Giampaolo Tortora, Tanios Bekaii-Saab, Armando Santoro, Joon Oh Park, Andrew Dean, Eric Van Cutsem, Jordan Berlin, Josep Tabernero, Andrew V Biankin
Förderung
- NCI NIH HHS
Zitieren
APA
Tempero, M. A., Pelzer, U., O'Reilly, E. M., Winter, J., Oh, D. Y., Li, C. P., Tortora, G., Chang, H. M., Lopez, C. D., Bekaii-Saab, T., Ko, A. H., Santoro, A., Park, J. O., Noel, M. S., Frassineti, G. L., Shan, Y. S., Dean, A., Riess, H., Van Cutsem, E., …, & APACT Investigators (2023). Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Journal of Clinical Oncology, 41(11), 2007-2019. https://doi.org/10.1200/jco.22.01134
Vancouver
Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, et al. Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Journal of Clinical Oncology. 2023;41(11):2007-2019. doi:10.1200/jco.22.01134
BibTeX
@article{Tempero2023,
author = {Tempero, Margaret A and Pelzer, Uwe and O'Reilly, Eileen M and Winter, Jordan and Oh, Do-Youn and Li, Chung-Pin and Tortora, Giampaolo and Chang, Heung-Moon and Lopez, Charles D and Bekaii-Saab, Tanios and Ko, Andrew H and Santoro, Armando and Park, Joon Oh and Noel, Marcus S and Frassineti, Giovanni Luca and Shan, Yan-Shen and Dean, Andrew and Riess, Hanno and Van Cutsem, Eric and Berlin, Jordan and Philip, Philip and Moore, Malcolm and Goldstein, David and Tabernero, Josep and Li, Mingyu and Ferrara, Stefano and Le Bruchec, Yvan and Zhang, George and Lu, Brian and Biankin, Andrew V and Reni, Michele and APACT Investigators, APACT Investigators},
title = {Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {11},
pages = {2007--2019},
doi = {10.1200/jco.22.01134}
}
EUVIMED